NasdaqCM - Nasdaq Real Time Price USD

AVITA Medical, Inc. (RCEL)

9.01

-0.01

(-0.11%)

As of 9:50:55 AM EDT. Market Open.

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDermVALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Ar

GlobeNewswire 7 days ago

AVHHL

RCEL
-0.11%
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and in

GlobeNewswire 13 days ago

AVHHL

RCEL
-0.11%
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm® Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to exp

GlobeNewswire 30 days ago

AVHHL

RCEL
-0.11%
Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Avita Medical (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

RCEL
-0.11%
AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

VALENCIA, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Jim Corbett, Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at https://ir.av

GlobeNewswire last month

AVHHL

RCEL
-0.11%
AVITA Medical, Inc. (RCEL): A Bull Case Theory

We came across a bullish thesis on AVITA Medical, Inc. (RCEL) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RCEL. AVITA Medical, Inc. (RCEL)’s share was trading at $10.22 as of Feb 19th. Avita Medical (RCEL) reported its Q4 2024 and full-year earnings, with strong revenue growth and expanding market […]

Insider Monkey last month

RCEL
-0.11%
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know

The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

RCEL
-0.11%
AVITA Medical Full Year 2024 Earnings: Misses Expectations

AVITA Medical ( NASDAQ:RCEL ) Full Year 2024 Results Key Financial Results Revenue: US$64.3m (up 28% from FY 2023). Net...

Simply Wall St. last month

AVHHL

RCEL
-0.11%
AVITA Medical to Host Investor Webinar Briefing

VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The

GlobeNewswire last month

AVHHL

RCEL
-0.11%
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024,

GlobeNewswire 2 months ago

AVHHL

RCEL
-0.11%
AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target. The U.S.-based company estimated its commercial revenue was about $64.3 million in fiscal 2024, lower than its forecast of $68 million to $70 million, due to slower-than-expected purchases from hospitals in the last quarter. AVITA's shares tumbled 18.8% to a two-month low of A$3.53, while the broader S&P/ASX 200 healthcare index was 0.7% higher.

Reuters 3 months ago

RCEL
-0.11%
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its fourth quarter and full-year 2024 commercial revenue guidance. For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4 million, reflecting growth of around 30% over the same period i

GlobeNewswire 3 months ago

AVHHL

RCEL
-0.11%
Exploring High Growth Tech Stocks in the United States December 2024

Over the last 7 days, the United States market has dropped 1.1%, yet it has risen by an impressive 22% over the past year, with earnings forecasted to grow by 15% annually. In this context of fluctuating short-term performance and promising long-term growth, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health to capitalize on future opportunities.

Simply Wall St. 3 months ago

AVHHL

RCEL
-0.11%
PGY
Cantor Fitzgerald bullish on Avita Medical after FDA approval for RECELL GO Mini

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat smaller wounds that aren’t addressed by RECELL GO. Importantly, the firm expects that approval for Mini will allow the company to target smaller wounds within the company’s full thickness skin defect indication. Cantor notes Avita plans to roll out Mini across trauma and burn centers that treat smaller wound

TipRanks 3 months ago

AVHHL

RCEL
-0.11%
Avita Medical initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of soft tissue and skin-related indications and Avita is “poised for significant growth” from expanding market penetration into trauma wounds, surgical wounds, and “slowly but surely chronic wounds” as awareness of the technology increases and adoption grows in hospitals and burn centers worldwide, the analyst

TipRanks 3 months ago

AVHHL

RCEL
-0.11%
FDA approves mini version of RECELL GO for smaller wounds

Avita’s RECELL platform uses the regenerative properties of the patient’s own skin for wound treatment.

Medical Device Network 3 months ago

RCEL
-0.11%
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

RECELL GO mini AVITA Medical receives FDA approval of RECELL GO mini, a new addition to the RECELL Spray-On Skin™ technology platform. VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® min

GlobeNewswire 3 months ago

AVHHL

RCEL
-0.11%
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDermCohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance fo

GlobeNewswire 3 months ago

AVHHL

RCEL
-0.11%
AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentat

GlobeNewswire 3 months ago

AVHHL

RCEL
-0.11%
Why Is AVITA Medical Inc. (RCEL) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where AVITA Medical Inc. (NASDAQ:RCEL) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry are […]

Insider Monkey 4 months ago

RCEL
-0.11%

Performance Overview

Return	RCEL	S&P 500 (^GSPC)
YTD	-29.61%	-9.81%
1-Year	-3.94%	+5.62%
3-Year	+19.34%	+20.76%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AVITA Medical, Inc. (RCEL)

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

Does Avita Medical (RCEL) Have the Potential to Rally 73.72% as Wall Street Analysts Expect?

AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference

AVITA Medical, Inc. (RCEL): A Bull Case Theory

Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know

AVITA Medical Full Year 2024 Earnings: Misses Expectations

AVITA Medical to Host Investor Webinar Briefing

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

Exploring High Growth Tech Stocks in the United States December 2024

Cantor Fitzgerald bullish on Avita Medical after FDA approval for RECELL GO Mini

Avita Medical initiated with a Buy at D. Boral Capital

FDA approves mini version of RECELL GO for smaller wounds

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is AVITA Medical Inc. (RCEL) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

Performance Overview